NACB - Scientific Shorts
NACB - Scientific Shorts (formerly NACB Blog)
By Dr. Wendy Alderton, Chief Scientific Officer, Abcodia Ltd, UK
Over recent decades good progress has been made in survival for many types of cancer, including breast, colorectal, testicular, and prostate cancers. But some types of malignancies, including pancreatic cancer, have remained resistant to efforts to improve outcomes. Pancreatic cancer has a 5 year r...(Read More)
By Olaia Rodriguez Fraga
Antineoplastic agents have progressed in a remarkable way over the last years. The introduction of targeted therapies has increased the cure and remission rates in some cancers and has even turned certain cancers into chronic diseases that can be controlled or managed for months or years.  However,...(Read More)
By Alicia Algeciras-Schimnich, PhD
​Serum thyroglobulin (Tg) measurement is used in the follow-up of patients with differentiated thyroid cancer following total thyroidectomy and radioactive iodine ablation. In athyrotic patients, thyroglobulin is an excellent tumor marker because it is produced exclusively by the follicular cells o...(Read More)
By D. Robert Dufour, MD, FACB
On October 11, the U.S. Preventive Services Task Force (USPSTF) issued a draft of updated recommendations relating to screening for prostate cancer with PSA, in which they made a recommendation not to screen for prostate cancer using PSA (grade D recommendations, moderate or high certainty that the...(Read More)
1 - 4 Next